BiVictriX Therapeutics PLC
LSE:BVX
BiVictriX Therapeutics PLC
LSE:BVX
Price:
11.5 GBX
-4.17%
Market Closed
Updated:
May 8, 2024
BiVictriX Therapeutics PLC
Net Income (Common)
|
BiVictriX Therapeutics PLC
Net Income (Common) Peer Comparison
Comparables:
CNTA
AUTL
BCYC
IMCR
GNS
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
BiVictriX Therapeutics PLC
LSE:BVX
|
Net Income (Common)
-£2.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Net Income (Common)
-$151.1m
|
CAGR 3-Years
-142%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Net Income (Common)
-$208.4m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Net Income (Common)
-$168.2m
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Net Income (Common)
-£55.3m
|
CAGR 3-Years
9%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Net Income (Common)
£33.4m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
3%
|
See Also
What is BiVictriX Therapeutics PLC's Net Income (Common)?
Net Income (Common)
-2.5m
GBP
-2.5m
GBP
Based on the financial report for Dec 31, 2022, BiVictriX Therapeutics PLC's Net Income (Common) amounts to -2.5m GBP.
What is BiVictriX Therapeutics PLC's Net Income (Common) growth rate?
Net Income (Common) CAGR 1Y
-7%
-7%
Over the last year, the Net Income (Common) growth was -7%.
You don't have any saved screeners yet
